Navigation Links
ClearWay Minnesota(SM) Adds New Director of Research
Date:8/13/2009

MINNEAPOLIS, Aug. 13 /PRNewswire/ -- ClearWay Minnesota announced today that Dr. Raymond Boyle, Ph.D., M.P.H., will be the new Director of Research for the organization. Dr. Boyle has training in Health Education and Epidemiology from the University of Oregon and the University of Minnesota.

"We are very excited about this new addition to ClearWay Minnesota and our research department," said David Willoughby, Chief Executive Officer of ClearWay Minnesota. "Dr. Boyle is well respected in his work on tobacco control and will help us continue to achieve our goals of reducing the harm of tobacco in Minnesota."

Prior to joining ClearWay Minnesota, Dr. Boyle was with the Department of Family Medicine and Community Health at the University of Minnesota Medical School. He has served as a research investigator for 10 clinical trials involving a wide variety of research topics including smoking and snuff cessation, weight loss among health plan members and adolescent health. In addition, Dr. Boyle has published more than 50 papers in peer-reviewed scientific journals.

About ClearWay Minnesota(SM)

ClearWay Minnesota is an independent, non-profit organization that improves the health of Minnesotans by reducing the harm caused by tobacco. ClearWay Minnesota serves Minnesota through its grant-making program, QUITPLAN(R) stop-smoking services and statewide outreach activities. It is funded with 3 percent of the state's 1998 tobacco settlement. For more information on ClearWay Minnesota or QUITPLAN Services, call 952-767-1400 or visit clearwaymn.org.


'/>"/>
SOURCE ClearWay Minnesota
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. ClearWay Minnesota(SM) Board Approves Four Regional Grants
2. ClearWay Minnesota(SM) Board Approves New Officers
3. ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobaccos Harm
4. ClearWay Minnesota(SM) Celebrates 10-Year Anniversary of Settlement
5. ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol
6. ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants
7. ClearWay Minnesota(SM) to Share Stories of Real Minnesotans Who Used QUITPLAN(R) Services During Great American Smokeout
8. Procter & Gamble Announces Appointment of Director
9. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
10. Jeff Korte Named as SIU Director, Litigation Solutions, LLC
11. Jim Deal Appointed to MedCaths Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Plainview, NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and ... delivery arm of one of world’s largest healthcare services providers. , According ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... telemedicine platform, in which their iMedSecure™ comes included with each system installation. ... live images to remote participants for real-time collaboration and immediate decision-making requirements. ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today the addition of ... in Biology from LSU, graduating summa cum laude. He attended Emory University School of ... in St. Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... PARK, N.C. , July 10, 2017 ... $5m Convertible Note to support the development of CRISPR-Cas3 ... Tencent Holdings Limited, a leading Chinese Internet services provider, ... funding will advance multiple infectious disease product programs targeting ... Founded by Dr. Rodolphe ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology: